Roche and Alnylam Highlight Data from the P-II (KARDIA-2) Trial of Zilebesiran for the Treatment of Hypertension
Shots:
- The P-II (KARDIA-2) study investigates the safety & efficacy of zilebesiran (600mg) when added to SoC, for the treatment of adults (n=672), randomized 1:1, with mild-to-moderate hypertension
- The study depicted reduced systolic blood pressure at mos. 3 with favorable safety & tolerability profile. The results were built upon the P-II (KARDIA-1) study findings & will be highlighted at the American College of Cardiology Annual Scientific Session 2024
- Roche and Alnylam have also started the P-II (KARDIA-3) trial to determine the effectiveness of zilebesiran plus two or more hypertension therapies in individuals with uncontrolled hypertension and who are at high cardiovascular risk
Ref: Roche | Image: Roche
Related News:- Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
